SOPHiA GENETICS SA (SOPH) Stock Forecast
SOPH analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 5 analysts
- Price target
- $9.75 average of analyst targets
- Upside to target
- +44.9% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.13
- 52-week range
- $3.89 – $8.92
SOPH analyst ratings
5 analystsNumber of analysts at each rating.
SOPH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SOPH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.20 | −$0.20 | −$0.20 | −$0.20 | −1.7% | 1 |
| Current fiscal year (2026) | −$0.85 | −$0.85 | −$0.85 | −$0.79 | −7.1% | 1 |
| Next fiscal year (2027) | −$0.50 | −$0.50 | −$0.50 | −$0.85 | +41.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SOPH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $24.0M | $23.5M | $24.5M | +23.5% | 5 |
| Current fiscal year (2026) | $95.2M | $95.0M | $95.7M | +23.2% | 5 |
| Next fiscal year (2027) | $118.7M | $113.7M | $128.1M | +24.6% | 5 |
SOPH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SOPH revenue: reported and forecast
SOPH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.19 | −$0.19 | −$0.19 | −$0.20 | +5.3% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.78 | −$0.78 | −$0.78 | −$0.78 | −$0.85 | +9.0% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.56 | −$0.56 | −$0.56 | −$0.56 | −$0.50 | −10.7% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SOPH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SOPH beat in 8 of 12.
What analysts expect from SOPH
5 analysts cover SOPHiA GENETICS; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.75, 44.9% above the latest close of $6.73. Analysts expect earnings of −$0.85 per share for 2026, −7.1% from a year earlier. For 2027 the average estimate is −$0.50 per share on revenue of $118.7 million. SOPHiA GENETICS beat the EPS estimate in 8 of the last 12 quarters.
Related: SOPH income statement, SOPH key metrics, SOPH chart. See the SOPH stock overview for the latest quote and news.
SOPH forecast FAQ
What is SOPHiA GENETICS's price target?
The average analyst price target for SOPHiA GENETICS is $9.75, 44.9% above the latest close of $6.73.
Is SOPHiA GENETICS a buy, hold or sell?
Of 5 analysts covering SOPHiA GENETICS, 5 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is SOPHiA GENETICS's EPS forecast?
Analysts forecast −$0.85 per share for 2026 (range −$0.85 to −$0.85); for 2027 the estimate is −$0.50.
What is SOPHiA GENETICS's revenue forecast?
The average revenue estimate for 2026 is $95.2 million, growth of 23.2%; for 2027 it is $118.7 million.
When does SOPHiA GENETICS report earnings?
SOPHiA GENETICS is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $-0.13.
Does SOPHiA GENETICS usually beat earnings estimates?
SOPHiA GENETICS reported EPS at or above the analyst estimate in 8 of the last 12 quarters.